semaglutide faa medical nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential FDA Approves Semaglutide As An

For patients with known cardiovascular disease, that context often drives decision-making more than the number on a scale

The body uses a lot of energy to fight off the infection, leaving the patient feeling drained

However, as use becomes more common in clinical practice, endocrinologists and primary care providers must balance glycemic outcomes, weight Read More GLP1s for Obesity: What LongTerm Treatment Really Means for Diabetes Care The rise of GLP-1 obesity treatment has transformed how clinicians approach patients with both obesity and diabetes

State of the art prediction of HIV-1 protease cleavage sites

MiRNA interacts with target gene mRNA and regulates the translation of functional proteins and various biological processes during carcinogenesis